Stem definition | Drug id | CAS RN |
---|---|---|
antineoplastics, nucleotoxic agents | 1820 | 53-19-0 |
None
Property | Value | Reference |
---|---|---|
BA (Bioavailability) | 40 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
July 8, 1970 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Adrenal insufficiency | 107.00 | 52.96 | 29 | 950 | 15668 | 56275420 |
Adrenocortical carcinoma | 72.91 | 52.96 | 9 | 970 | 49 | 56291039 |
Drug clearance increased | 60.17 | 52.96 | 8 | 971 | 84 | 56291004 |
Febrile neutropenia | 56.06 | 52.96 | 30 | 949 | 105515 | 56185573 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Adrenal insufficiency | 97.45 | 44.52 | 25 | 458 | 12634 | 31684227 |
Adrenocortical carcinoma | 59.63 | 44.52 | 7 | 476 | 27 | 31696834 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Adrenal insufficiency | 189.15 | 47.59 | 52 | 1405 | 25143 | 70901844 |
Adrenocortical carcinoma | 111.28 | 47.59 | 14 | 1443 | 75 | 70926912 |
Drug clearance increased | 58.33 | 47.59 | 9 | 1448 | 239 | 70926748 |
Febrile neutropenia | 57.11 | 47.59 | 41 | 1416 | 204277 | 70722710 |
Neutropenia | 55.08 | 47.59 | 44 | 1413 | 257112 | 70669875 |
None
Source | Code | Description |
---|---|---|
ATC | L01XX23 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D018931 | Antineoplastic Agents, Hormonal |
FDA MoA | N0000185506 | Cytochrome P450 3A4 Inducers |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Carcinoma in situ of adrenal cortex | indication | 92526009 | |
Hypercortisolism | off-label use | 47270006 | |
Shock | contraindication | 27942005 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
Breastfeeding (mother) | contraindication | 413712001 | |
Traumatic injury | contraindication | 417746004 | |
CNS Toxicity | contraindication |
None
None
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Cytochrome P450 11B1, mitochondrial | Enzyme | INHIBITOR | WOMBAT-PK | CHEMBL | |||||
Cholesterol side-chain cleavage enzyme, mitochondrial | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 6.09 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.51 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.19 | DRUG MATRIX | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.56 | DRUG MATRIX | |||||
Adenosine receptor A3 | GPCR | Ki | 5.38 | DRUG MATRIX | |||||
Adrenodoxin, mitochondrial | Unclassified | WOMBAT-PK | |||||||
Sodium-dependent dopamine transporter | Transporter | Ki | 6.10 | DRUG MATRIX | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 5.80 | DRUG MATRIX |
ID | Source |
---|---|
4018140 | VUID |
N0000146477 | NUI |
D00420 | KEGG_DRUG |
4018140 | VANDF |
C0026256 | UMLSCUI |
CHEBI:6954 | CHEBI |
CHEMBL1670 | ChEMBL_ID |
DB00648 | DRUGBANK_ID |
D008939 | MESH_DESCRIPTOR_UI |
4211 | PUBCHEM_CID |
6957 | IUPHAR_LIGAND_ID |
2597 | INN_ID |
78E4J5IB5J | UNII |
204257 | RXNORM |
1449 | MMSL |
5123 | MMSL |
d01378 | MMSL |
002669 | NDDF |
26288002 | SNOMEDCT_US |
404865004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Lysodren | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76336-080 | TABLET | 500 mg | ORAL | NDA | 24 sections |